June 29, 2026—Roche has launched the Axelios 1, a next‑generation single-molecule sequencing platform powered by proprietary sequencing by expansion (SBX) technology.
The platform converts DNA or RNA into high signal‑to‑noise Xpandomers, which are measured by a sequencing instrument using a reusable complementary metal-oxide semiconductor sensor containing millions of nanopores. “This architecture enables accurate, ultra‑rapid, flexible, and high‑throughput, single‑molecule sequencing with near real‑time analysis,” according to a press announcement from the company.
Designed for flexibility and performance, the Axelios 1 platform can be used for smaller, faster batches or larger projects without changing systems or workflows and is capable of producing whole genome results the same day. Roche will be offering library prep kits and a free open-source bioinformatics analysis suite tailored for SBX technology. In addition, the platform is built to allow for the use of other life sciences tools, enabling compatibility across a breadth of research applications.
Since the SBX technology was unveiled in early 2025, multiple research applications have been tested on the technology, including whole genome sequencing, RNA sequencing, single‑cell RNA, spatial, and methylation, among others. Early‑access users have also demonstrated practical research applications across oncology, genetics, and infectious diseases.
Axelios 1 is for research use only. Not for use in diagnostic procedures.